Entering text into the input field will update the search result below

J&J files European marketing application for expanded use of Darzalex

Mar. 22, 2019 8:22 AM ETJohnson & Johnson (JNJ) Stock, CELG Stock, GNMSF StockGMABBy: Douglas W. House, SA News Editor
  • Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutica NV has filed a supplemental marketing application in Europe seeking approval to use DARZALEX (daratumumab), combined with Celgene's (NASDAQ:CELG) REVLIMID (lenalidomide) and dexamethasone, to treat multiple myeloma patients who are not candidates for high-dose chemo and autologous stem cell transplant.
  • Janssen in-licensed global rights to daratumumab from Genmab A/S (OTCPK:GNMSF) in August 2012.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
CELG
--
JNJ
--
GNMSF
--